Literature DB >> 19679627

Potency of andrographolide as an antitumor compound in BHC-induced liver damage.

Neha P Trivedi1, Upendra M Rawal, Beena P Patel.   

Abstract

RELEVANCE: The present investigation relates to the influence of andrographolide, an active compound of Andrographis paniculata Nees. It reverses an experimental liver carcinogenic condition of mice to normal and might be a potential therapeutic/preventive agent for human liver cancer.
OBJECTIVE: A. paniculata (Kalmegh) is extensively used in the Indian traditional system of medicine as a hepatoprotective and hepatostimulative agent and has been reported to have protective effect against different hepatotoxins.
MATERIALS AND METHODS: Histomorphological, ultrastructural, and biochemical studies were performed for the effect of the andrographolide on control mice, mice treated with hexachlorocyclohexane (BHC) only and BHC + andrographolide. Enzymes for liver function tests were analyzed by spectrophotometric method.
RESULTS: The BHC experimental model forms an irreversible liver tumor in male mice. The histological and ultrastructural changes observed in andrographolide supplementation emphasize the recovery of the damaged liver. This recovery was also reflected in the neoplastic nodule formation. The activity of phosphorylase and glucose-6-phosphatase in the liver of the andrographolide-supplemented group suggests improved glycogenolysis in liver. Serum glutamate pyruvate transaminase, serum glutamate oxalate transaminase, alkaline phosphatase, acid phosphatase, and gamma-glutamyl transpeptidase showed a significant decrease in andrographolide-supplemented animals as compared with BHC-treated animals, suggesting regenerative effects elicited by andrographolide.
CONCLUSION: The study indicates that the regenerative capability elicited by andrographolide is possibly due to its ability to reactivate liver function enzymes that catalyze the reaction of several biochemical and synthetic processes and that it may be useful for severe liver damage conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679627     DOI: 10.1177/1534735409335606

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  6 in total

1.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

2.  Terpenoids as potential chemopreventive and therapeutic agents in liver cancer.

Authors:  Roslin J Thoppil; Anupam Bishayee
Journal:  World J Hepatol       Date:  2011-09-27

3.  Regioselective glucuronidation of andrographolide and its major derivatives: metabolite identification, isozyme contribution, and species differences.

Authors:  Xiangge Tian; Sicheng Liang; Chao Wang; Baojian Wu; Guangbo Ge; Sa Deng; Kexin Liu; Ling Yang; Xiaochi Ma
Journal:  AAPS J       Date:  2014-09-10       Impact factor: 4.009

4.  Andrographolide sodium bisulphite-induced inactivation of urease: inhibitory potency, kinetics and mechanism.

Authors:  Zhi-Zhun Mo; Xiu-Fen Wang; Xie Zhang; Ji-Yan Su; Hai-Ming Chen; Yu-Hong Liu; Zhen-Biao Zhang; Jian-Hui Xie; Zi-Ren Su
Journal:  BMC Complement Altern Med       Date:  2015-07-16       Impact factor: 3.659

5.  Andrographolide impedes cancer stemness and enhances radio-sensitivity in oral carcinomas via miR-218 activation.

Authors:  Po-Yu Yang; Pei-Ling Hsieh; Tong Hong Wang; Cheng-Chia Yu; Ming-Yi Lu; Yi-Wen Liao; Tzu-Hsin Lee; Chih-Yu Peng
Journal:  Oncotarget       Date:  2017-01-17

Review 6.  Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability.

Authors:  João Paulo Loureiro Damasceno; Hemerson Silva da Rosa; Luciana Silva de Araújo; Niege Araçari Jacometti Cardoso Furtado
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-11-23       Impact factor: 2.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.